These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17334589)

  • 1. Reduced expression of alpha-tocopherol-associated protein is associated with tumor cell proliferation and the increased risk of prostate cancer recurrence.
    Wen XQ; Li XJ; Su ZL; Liu Y; Zhou XF; Cai YB; Huang WT; Gao X
    Asian J Androl; 2007 Mar; 9(2):206-12. PubMed ID: 17334589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
    Ni J; Wen X; Yao J; Chang HC; Yin Y; Zhang M; Xie S; Chen M; Simons B; Chang P; di Sant'Agnese A; Messing EM; Yeh S
    Cancer Res; 2005 Nov; 65(21):9807-16. PubMed ID: 16267002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
    Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
    In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
    Kishi H; Igawa M; Kikuno N; Yoshino T; Urakami S; Shiina H
    J Urol; 2004 May; 171(5):1855-60. PubMed ID: 15076293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
    Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
    Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
    Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
    Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
    Buschemeyer WC; Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2008 Jan; 179(1):124-9; discussion 129. PubMed ID: 17997433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
    Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
    Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence.
    Marks RA; Lin H; Koch MO; Cheng L
    Am J Surg Pathol; 2007 Jun; 31(6):877-81. PubMed ID: 17527074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
    Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
    Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.